Biology

Chorioamnionitis

Gestation

Inflammatory bowel disease

Placental abruption

Genetics

Gestational diabetes

Gestational age

Internal medicine

Obstetrics

Odds ratio

Medicine

Disease

Premature rupture of membranes

Pregnancy

Alimentary Pharmacology & Therapeutics

Summary Background The effect of inflammatory bowel disease (IBD) on pregnancy‐related outcomes remains unknown. Aim To determine the risk of adverse maternal, placental and obstetric outcomes in IBD Methods We searched Medline, Embase and Cochrane library through May 2019 for studies reporting adverse maternal, placental and obstetric outcomes in patients with IBD. Odds ratios (OR) with 95% confidence intervals (CI) were calculated for these outcomes in patients with IBD compared to healthy controls. Results Fifty‐three studies were included (7917 IBD pregnancies and 3253 healthy control pregnancies). Caesarean delivery was more common in patients with IBD compared to healthy controls (OR 1.79, 95% CI, 1.16‐2.77). This remained significant for UC (OR 1.80, 95% CI, 1.21‐2.90) but not CD (OR 1.48, 95% CI, 0.94‐2.34). Similarly, gestational diabetes occurred more commonly in IBD (OR 2.96, 95% CI, 1.47‐5.98). The incidences of placental diseases were 2.0% (95% CI, 0.9%‐3.1%) for pre‐eclampsia, 3.3% (95% CI, 0%‐7.2%) for placental abruption, 0.5% (95% CI, 0.2%‐0.9%) for placenta previa and 0.3% (95% CI, 0%‐0.5%) for chorioamnionitis. Patients with IBD were more likely to experience preterm prelabour rupture of membranes (OR 12.10, 95% CI, 2.15‐67.98), but not early pregnancy loss (OR 1.63, 95% CI 0.49‐5.43). Anti‐tumour necrosis factor therapy was not associated with chorioamnionitis (OR 1.12, 95% CI, 0.16‐7.67), early pregnancy loss (OR 1.49, 95% CI, 0.83‐2.64) or placenta previa (OR 1.58, 95% CI, 0.30‐8.47). Conclusions Gestational diabetes and preterm prelabour rupture of membranes occurs more commonly in patients with IBD, although the incidence of placental diseases remains low.

Systematic review with meta‐analysis: risk of adverse pregnancy‐related outcomes in inflammatory bowel disease